Overview

AMPK-activation by Metformin in FSGS: AMP-FSGS

Status:
Recruiting

Trial end date:
2027-11-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to determine whether extended-release MF (in addition to standard of care (S-o-C)) is superior to placebo in reducing podocyte injury and promoting podocyte survival by 6-months in Focal Segmental Glomerulosclerosis (FSGS).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Yale University

Collaborator:

United States Department of Defense

Treatments:

Metformin